证券代码：603205 证券简称：健尔康 公告编号：2025-035 健尔康医疗科技股份有限公司 第二届董事会第十六次会议决议公告 健尔康医疗科技股份有限公司（以下简称"公司"）第二届董事会第十六次 会议于 2025 年 12 月 29 日以现场结合通讯的方式在公司会议室召开，会议通知 于 2025 年 12 月 19 日以书面方式送达。本次会议由董事长陈国平先生主持，应 到董事 9 人，实到董事 9 人。本次董事会的召集、召开和表决程序符合《中华人 民共和国公司法》等有关法律法规及《健尔康医疗科技股份有限公司章程》的规 定。 二、董事会会议审议情况 经全体董事逐项审议，会议表决情况如下： （一）审议通过《关于使用部分暂时闲置募集资金进行现金管理的议案》 本议案已经董事会审计委员会全体同意，并同意提交公司董事会审议。 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）上披露 的《关于使用部分暂时闲置募集资金进行现金管理的公告》（公告编号： 2025-036）。 表决结果：9 票同意、0 票反对、0 票弃权。 （二）审议通过《关于使用闲置自有资金进行现金管理的议案》 本公司董事会及全体董 ...

Core Viewpoint - The company plans to utilize up to 280 million yuan of temporarily idle raised funds for cash management, investing in low-risk and liquid financial products that meet capital preservation requirements [1] Group 1: Board Meetings - The company will hold the 11th meeting of the second board's audit committee on December 19, 2025, and the 16th meeting of the second board on December 29, 2025 [1] Group 2: Fund Management - The company intends to invest in safe and liquid financial products, including but not limited to agreed deposits, time deposits, large-denomination certificates of deposit, and capital-preserving income certificates [1] - The approved fund management plan is valid for 12 months from the date of board approval, allowing for rolling use of funds within the specified limit [1] - The company assures that this cash management will not affect the progress of the raised fund investment projects or the normal production and operation of the company [1]

Market Overview - The medical device sector experienced a decline of 0.74% on December 29, with Huakang Clean leading the drop [1] - The Shanghai Composite Index closed at 3965.28, up 0.04%, while the Shenzhen Component Index closed at 13537.1, down 0.49% [1] Top Performers - Meihao Medical (301363) saw a closing price of 25.04, with an increase of 8.30% and a trading volume of 197,100 shares, totaling a transaction value of 482 million yuan [1] - Mailande (688273) closed at 41.73, up 8.22%, with a trading volume of 55,200 shares and a transaction value of 227 million yuan [1] - Kangzhong Medical (688607) closed at 45.80, up 7.23%, with a trading volume of 40,200 shares and a transaction value of 180 million yuan [1] Underperformers - Huakang Clean (301235) closed at 39.21, down 8.54%, with a trading volume of 123,300 shares and a transaction value of 488 million yuan [2] - C Jianxin (688805) closed at 47.16, down 7.26%, with a trading volume of 89,000 shares and a transaction value of 426 million yuan [2] - Furuim Medical (300049) closed at 71.93, down 4.20%, with a trading volume of 66,800 shares and a transaction value of 485 million yuan [2] Capital Flow - The medical device sector saw a net outflow of 565 million yuan from institutional investors, while retail investors experienced a net inflow of 328 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are more active [2] Individual Stock Capital Flow - Meihao Medical (301363) had a net outflow of 54.30 million yuan from institutional investors, with retail investors also showing a net outflow of 0.76 million yuan [3] - Jigaofazhan (600807) experienced a net inflow of 44.75 million yuan from institutional investors, while retail investors had a net outflow of 61.29 million yuan [3] - Kangzhong Medical (688626) saw a net inflow of 44.26 million yuan from institutional investors, with retail investors showing a slight net outflow [3]

12月18日，健尔康涨4.00%，成交额7267.47万元。两融数据显示，当日健尔康获融资买入额994.45万 元，融资偿还837.07万元，融资净买入157.38万元。截至12月18日，健尔康融资融券余额合计6334.20万 元。 融券方面，健尔康12月18日融券偿还600.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量6600.00股，融券余额18.71万元，超过近一年90%分位水平，处于高位。 资料显示，健尔康医疗科技股份有限公司位于江苏省常州市金坛区直溪镇工业集中区健尔康路1号，成 立日期2000年6月6日，上市日期2024年11月7日，公司主营业务涉及医用敷料等一次性医疗器械及消毒 卫生用品研发、生产和销售。主营业务收入构成为：护理产品33.19%，手术耗材产品30.64%，高分子 及辅助类产品18.46%，消毒清洁产品16.93%，其他0.79%。 融资方面，健尔康当日融资买入994.45万元。当前融资余额6315.49万元，占流通市值的5.39%，融资余 额低于近一年30%分位水平，处于低位。 截至9月30日，健尔康股东户数1.71万，较上期减少6.15%；人均流通 ...

Group 1 - The core point of the news is that Jianerkang's stock price has increased for six consecutive days, with a total increase of 7.34% during this period, reaching a price of 28.66 yuan per share and a market capitalization of 4.471 billion yuan [1] - Jianerkang Medical Technology Co., Ltd. specializes in the research, production, and sales of disposable medical devices and disinfectant hygiene products, with its main business revenue composition being: nursing products 33.19%, surgical consumables 30.64%, polymer and auxiliary products 18.46%, disinfecting and cleaning products 16.93%, and others 0.79% [1] - The company is located in Jiangsu Province, China, and was established on June 6, 2000, with its listing date set for November 7, 2024 [1] Group 2 - Among Jianerkang's top ten circulating shareholders, a fund under Yongying Fund ranks first, and the Medical Device ETF (159883) entered the top ten circulating shareholders in the third quarter, holding 285,100 shares, which is 0.73% of the circulating shares [2] - The Medical Device ETF (159883) was established on April 22, 2021, with a latest scale of 4.73 billion yuan, and has recorded a year-to-date return of 4.89% [2] - The fund manager of the Medical Device ETF is Shu Kefa, who has been in the position for 2 years and 111 days, with the fund's total asset scale at 6.282 billion yuan [3]

Core Insights - The stock of Jianerkang experienced a decline of 0.85% on November 18, with a trading volume of 28.09 million yuan [1] - The company reported a net financing outflow of 1.45 million yuan on the same day, indicating a low financing balance compared to historical levels [1] - Jianerkang's main business includes the development, production, and sales of disposable medical devices and disinfectant hygiene products, with a revenue composition heavily weighted towards nursing products and surgical consumables [1] Financing and Trading Data - On November 18, Jianerkang had a financing buy-in amount of 1.76 million yuan, with a total financing balance of 65.11 million yuan, representing 5.60% of its market capitalization [1] - The financing balance is below the 30th percentile of the past year, indicating a low level of financing activity [1] - No shares were sold or repaid in the securities lending market on the same day, with a remaining balance of 100 shares valued at 2,814 yuan, which is above the 70th percentile of the past year [1] Financial Performance - For the period from January to September 2025, Jianerkang reported a revenue of 725 million yuan, a year-on-year decrease of 7.35%, and a net profit attributable to shareholders of 76.41 million yuan, down 18.24% year-on-year [2] - The number of shareholders decreased by 6.15% to 17,100, while the average number of circulating shares per person increased by 38.51% to 2,286 shares [2] Shareholder and Dividend Information - Since its A-share listing, Jianerkang has distributed a total of 42.12 million yuan in dividends [3] - As of September 30, 2025, the largest circulating shareholder is the Medical Device ETF (159883), which holds 285,100 shares as a new shareholder [3]

Group 1 - The core viewpoint of the news is that Jianerkang's stock performance and financial metrics indicate a decline in revenue and profit, alongside low financing levels and high short-selling ratios [1][2][3] Group 2 - On November 17, Jianerkang's stock fell by 1.01%, with a trading volume of 31.38 million yuan. The financing buy-in amount was 3.95 million yuan, while the net financing buy-in was 1.01 million yuan, indicating low investor confidence [1] - As of November 17, the total financing and securities lending balance for Jianerkang was 66.57 million yuan, with financing balance accounting for 5.67% of the circulating market value, which is below the 40th percentile of the past year [1] - The company reported a revenue of 725 million yuan for the first nine months of 2025, a year-on-year decrease of 7.35%, and a net profit of 76.41 million yuan, down 18.24% year-on-year [2] - Jianerkang's main business revenue composition includes nursing products (33.19%), surgical consumables (30.64%), polymer and auxiliary products (18.46%), and disinfection and cleaning products (16.93%) [1] - As of September 30, 2025, the number of shareholders for Jianerkang was 17,100, a decrease of 6.15%, while the average circulating shares per person increased by 38.51% to 2,286 shares [2] - The company has distributed a total of 42.12 million yuan in dividends since its A-share listing [3] - The largest circulating shareholder as of September 30, 2025, is the Medical Device ETF (159883), which holds 285,100 shares as a new shareholder [3]

Core Viewpoint - The company has approved the use of idle raised funds for cash management, allowing for a maximum of RMB 350 million to be utilized within a 12-month period [1][2]. Group 1: Fund Management Approval - The company's board and supervisory board approved the proposal to use idle raised funds for cash management on November 18, 2024 [1]. - The maximum amount for cash management is set at RMB 350 million, which can be rolled over within the specified period [1]. - The management is authorized to make decisions regarding the use of these funds, with the finance department responsible for implementation [1]. Group 2: Investment and Redemption - On June 5, 2025, the company invested RMB 35 million of the idle funds in a customized income certificate from Shenwan Hongyuan Securities [2]. - The investment product was redeemed on November 12, 2025, with the specific returns to be confirmed upon settlement [2].

注：相关收益为预计收益，具体金额以实际结算金额为准。 特此公告。 健尔康医疗科技股份有限公司 董事会 2025 年 11 月 13 日 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 健尔康医疗科技股份有限公司（以下简称"公司"）于 2024 年 11 月 18 日 召开第二届董事会第十一次会议及第二届监事会第六次会议分别审议通过了《关 于使用部分暂时闲置募集资金进行现金管理的议案》，同意公司使用闲置募集资 金不超过人民币 3.5 亿元（单日最高余额，含本数）进行现金管理，上述额度可 以滚动使用，自第二届董事会第十一次会议审议通过之日起 12 个月（含）内有 效，并授权公司管理层在上述额度内行使决策权，具体事项由公司财务部负责组 织实施。具体内容详见公司于 2024 年 11 月 19 日披露于上海证券交易所网站 （www.sse.com.cn）的《健尔康医疗科技股份有限公司关于使用部分暂时闲置募 集资金进行现金管理的公告》（公告编号：2024-003）。 2025 年 6 月 5 日，公司使用部分闲置募集资金人民币 3, ...

Group 1 - The core viewpoint of the news is that Jianerkang has experienced a decrease in both revenue and net profit for the first nine months of 2025, alongside changes in shareholder structure and financing activities [2][3] - As of November 5, Jianerkang's stock price increased by 0.32%, with a trading volume of 20.99 million yuan and a net financing buy of -847,500 yuan [1] - The company has a total financing and securities balance of 64.10 million yuan, which accounts for 5.82% of its circulating market value [1] Group 2 - For the period from January to September 2025, Jianerkang reported an operating income of 725 million yuan, a year-on-year decrease of 7.35%, and a net profit attributable to shareholders of 76.41 million yuan, down 18.24% year-on-year [2] - The company has distributed a total of 42.12 million yuan in dividends since its A-share listing [3] - As of September 30, 2025, Jianerkang had 17,100 shareholders, a decrease of 6.15% from the previous period, with an average of 2,286 circulating shares per person, an increase of 38.51% [2]